1. Home
  2. FRD vs CDXS Comparison

FRD vs CDXS Comparison

Compare FRD & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Friedman Industries Inc.

FRD

Friedman Industries Inc.

HOLD

Current Price

$20.40

Market Cap

146.2M

Sector

Industrials

ML Signal

HOLD

Logo Codexis Inc.

CDXS

Codexis Inc.

HOLD

Current Price

$1.30

Market Cap

141.8M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
FRD
CDXS
Founded
1965
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Steel/Iron Ore
Major Chemicals
Sector
Industrials
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
146.2M
141.8M
IPO Year
N/A
2010

Fundamental Metrics

Financial Performance
Metric
FRD
CDXS
Price
$20.40
$1.30
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
14.3K
925.3K
Earning Date
02-06-2026
02-26-2026
Dividend Yield
0.78%
N/A
EPS Growth
43.48
N/A
EPS
1.63
N/A
Revenue
$510,450,000.00
$52,932,000.00
Revenue This Year
N/A
$15.64
Revenue Next Year
N/A
$5.23
P/E Ratio
$12.61
N/A
Revenue Growth
8.72
N/A
52 Week Low
$12.24
$1.22
52 Week High
$23.50
$4.51

Technical Indicators

Market Signals
Indicator
FRD
CDXS
Relative Strength Index (RSI) 57.02 37.26
Support Level $18.25 $1.22
Resistance Level $19.95 $1.48
Average True Range (ATR) 0.82 0.14
MACD 0.17 -0.03
Stochastic Oscillator 85.38 10.53

Price Performance

Historical Comparison
FRD
CDXS

About FRD Friedman Industries Inc.

Friedman Industries Inc is engaged in the manufacturing and processing of steel products. The company's operating segments include flat-roll products and Tubular Products. It generates maximum revenue from the flat-roll products segment. The company's products and services include Temper Pass, Cut-To-Length, Whole Coils, Toll Processing, Electric Resistance Welded Pipe (ERW), New Mill Secondary, and Pipe Finishing Services.

About CDXS Codexis Inc.

Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.

Share on Social Networks: